[三季报]健康元(600380):健康元药业集团股份有限公司2025年第三季度报告（英文）
|
时间：2025年10月24日 23:40:57 中财网 |
|
原标题: 健康元: 健康元药业集团股份有限公司2025年第三季度报告（英文）
Stock Code: 600380 Stock Short Name: 健康元
Joincare Pharmaceutical Group Industry Co., Ltd.
2025 Third Quarterly Report
The Board of Directors and all Directors of the Company hereby warrant that there are no false representations, misleading statements or material omissions contained in this announcement and accept legal responsibility for the truthfulness, accuracy and completeness of the contents hereof.
IMPORTANT NOTICE:
? The Board of Directors, the Board of Supervisors and Directors, Supervisors and senior management
of the Company hereby warrant the truthfulness, accuracy and completeness of the contents of this quarterly report, and that there are no false representations, misleading statements or material omissions contained herein, and severally and jointly accept legal responsibility. ? The person-in-charge of the Company, the person-in-charge of accounting work and the person-in-charge of the accounting department (the head of the accounting department) hereby warrant the truthfulness, accuracy and completeness of the financial information contained in this quarterly report.
? Whether the first quarterly financial statements have been audited. □Yes √No
I. MAJOR FINANCIAL DATA
(I) Major Accounting Data and Financial Indicators
Unit: Yuan Currency: RMB
| Item | For the
Reporting
Period | YoY change
(%) | From the
beginning of the
year to the end of
the Reporting
Period | YoY change (%) | | Revenues | 3,579,478,699.21 | -2.31 | 11,477,806,949.62 | -3.54 | | Total Profits | 779,993,613.25 | -6.84 | 2,852,735,638.71 | 1.19 | | Net profit attributable to
shareholders of the listed
company | 306,274,217.94 | -8.61 | 1,091,214,131.28 | -1.83 | | Net profit attributable to
shareholders of the listed
company after deduction
of extraordinary gains
and losses | 288,317,700.24 | -7.43 | 1 ,0 5 8 , 1 3 0 ,8 1 7 . 5 4 | - 1 .4 2 | | Net cash flow from
operating activities | N/A | N/A | 3,001,401,972.07 | 14.84 | | Basic earnings per share
(RMB/share) | 0.17 | -5.56 | 0.60 | 1.69 | | Diluted earnings per
share (RMB/share) | 0.17 | -5.56 | 0.60 | 1.69 | | Weighted average return
on net assets (%) | 2.08 | Decreased by 0.24
percentage points | 7.46 | Decreased by 0.36
percentage points | | | As at the end of
the Reporting
Period | As at the end of the previous year | Ending amount of
the Reporting
Period to that of
the previous year
(%) | | | Total assets | 36,013,652,752.26 | 35,718,129,456.13 | 0.83 | | | Owner's equity
attributable to
shareholders of the listed
company | 14,866,521,304.45 | 14,534,719,589.34 | 2.28 | |
Notes: The “Reporting Period” represents the 3-month period from the beginning to the end of this
quarter, the same as below.
(II) Items and Amounts of Extraordinary Gains and Losses
√Applicable □N/A
| Item | For the
Reporting Period | From the beginning of the
year to the end of the
Reporting Period | | Gains and losses on disposal of non-current assets
(including the reversal of previously recognized asset
impairment provisions) | -121,786.15 | -2,701,246.92 | | Government grants recognized in profit or loss for the
current period (excluding government grants that are
closely related to the business of the Company and are
provided in fixed amount or quantity continuously
according to the applicable policies and standards of the
country). | 32,335,118.66 | 100,774,158.82 | | Excluding effective hedging activities related to the
company's ordinary operating business, this refers to
gains and losses arising from changes in the fair value of
financial assets and financial liabilities held by non-
financial enterprises, as well as gains and losses from the
disposal of financial assets and financial liabilities. | 15,170,862.46 | 7,419,522.58 | | Other non-operating income and expenses excluding the
above items | -9,419,169.50 | -16,481,861.76 | | Less: Effect of income tax | 3,889,501.81 | 15,778,858.39 | | Effect of minority equity (after tax) | 16,119,005.96 | 40,148,400.59 | | Total | 17,956,517.70 | 33,083,313.74 |
For the items not listed in the “Explanatory Announcement No.1 for Public Company Information Disclosures-Extraordinary Gains or Losses” that the company identifies as non-recurring gains and losses,
especially those with significant amounts, as well as the extraordinary gain or loss items as illustrated in
the “Explanatory Announcement No.1 for Public Company Information Disclosures-Extraordinary Gains or Losses” which has been defined as its recurring gain or loss items, the reasons for such classification
should be explained.
□Applicable √N/A
(III) Changes in Major Accounting Data and Financial Indicators and Reasons Thereof □Applicable √N/A
(IV) Material Changes in Other Items in Financial Statements and Financial Indicators and Reasons Thereof
| Balance Sheet | 30 September
2025 | 31 December
2024 | Change in
proportion
(%) | Main Reason | | Financial assets held for
trading | 1,205,846,281.06 | 89,363,055.07 | 1,249.38 | Primarily due to the increase
in structured deposits during
the period. | | Other receivables | 70,426,958.95 | 51,166,649.86 | 37.64 | Primarily due to the increase
in export tax refund
receivables and other items
during the period. | | Non-current assets due
within one year | 821,335,346.22 | 556,410,803.22 | 47.61 | Primarily due to the transfer
of long-term cash
management products
maturing within one year. | | Other current assets | 232,152,185.08 | 159,087,536.76 | 45.93 | Primarily due to the addition
of short-term cash
management products. | | Development
expenditures | 516,552,277.31 | 362,703,730.11 | 42.42 | Primarily due to increased
R&D investment in Phase III
clinical trials for relevant
projects during the period. | | Other non-current assets | 663,773,428.95 | 1,273,057,844.54 | -47.86 | Primarily due to the transfer
out of long-term cash
management products
maturing within one year. | | Contract liabilities | 87,619,945.54 | 142,395,539.21 | -38.47 | Primarily due to the
recognition of revenue from
certain contract advances
that met the revenue
recognition criteria during
the period. | | Other current liabilities | 5,048,262.96 | 11,841,940.51 | -57.37 | Primarily due to the
recognition of revenue from
certain contract advances
that met the revenue
recognition criteria during
the period, and the
corresponding output VAT
was recognized. | | Capital reserve | 1,025,263,624.61 | 1,654,383,491.41 | -38.03 | Primarily due to the
cancellation of repurchased
shares during the period,
which was charged against
capital reserves. | | Treasury shares | - | 328,221,279.42 | -100.00 | Primarily due to the full
cancellation of repurchased
company shares. | | Other comprehensive
income | -86,037,198.18 | -41,177,547.42 | N/A | Primarily due to changes in
foreign currency translation
differences arising from
exchange rate fluctuations. | | Statement of Income | January to
September 2025 | January to
September 2024 | Change in
proportion
(%) | Main Reason | | Financial expenses | -262,734,133.56 | -105,969,421.63 | N/A | Primarily due to the increase
in deposit interest income
during the period. | | Gains from changes in
fair values | 3,330,943.14 | -5,736,443.62 | N/A | Primarily due to fluctuations
in the market value of the
Company’s securities
investments. | | Credit impairment loss | -10,074,239.15 | -797,210.83 | N/A | Primarily due to the increase
in expected credit losses on
receivables. | | Assets impairment loss | -20,885,370.43 | -113,694,072.70 | N/A | Primarily due to the decrease
in provision for inventory
write-downs and impairment
losses on development
expenditures. |
II. SHAREHOLDERS
(I) Total Number of Holders of Ordinary Shares and Number of Holders of Preferred Shares with Restored
Voting Rights and Shareholdings of Top 10 Shareholders
Unit: shares
| Total number of holders of ordinary
shares as of the end of the Reporting
Period | 81,433 | Total number of holders of preferred
shares with restored voting rights as of the
end of the Reporting Period (if any) | N/A | | | | | Shareholdings of the top 10 shareholders
（excluding shares lent through refinancing business） | | | | | | | | Name of shareholder | Nature of
shareholder | Number of
shares held | Percentage
(%) | Number of
shares held
with selling
restrictions | Pledge, mark or lock-up | | | | | | | | Share
status | Number | | Shenzhen Baiyeyuan Investment Co., Ltd.
(深圳市百业源投资有限公司) | Domestic non-
state-owned
legal person | 895,653,653 | 48.96 | 0 | None | | | Might Seasons Limited | Foreign legal
person | 35,929,699 | 1.96 | 0 | Unknown | | | Hong Kong Securities Clearing Company
Limited | Unknown | 34,206,023 | 1.87 | 0 | Unknown | | | Zhang Yongliang | Domestic
natural person | 16,242,296 | 0.89 | 0 | Unknown | | | Agriculture Bank of China Limited-CSI
500 Exchange Traded Index Securities
Investment Fund | Unknown | 15,938,148 | 0.87 | 0 | Unknown | | | Tang Wusheng | Domestic
natural person | 13,233,300 | 0.72 | 0 | Unknown | | | Rui Life Insurance Co., Ltd. -Own fund | Unknown | 12,739,218 | 0.70 | 0 | Unknown | | | Bank of Shanghai Co., Ltd.－Yinhua CSI
Innovative Drug Industry Trading Open-
end Index Securities Investment Fund | Unknown | 10,682,920 | 0.58 | 0 | Unknown | | | Joincare Pharmaceutical Group Industry
Co., Ltd. — the Third Phase Ownership
Scheme under Medium to Long-term
Business Partner Share Ownership
Scheme | Others | 9,370,400 | 0.51 | 0 | None | | | CPIC Fund -China Pacific Life Insurance
Co., Ltd. -with-profit insurance-CPIC
Fund China Pacific Life Equity Relative
Income (Guaranteed Dividend) single
asset management plan | Unknown | 7,957,200 | 0.43 | 0 | Unknown | | | Shareholdings of the top 10 shareholders without selling restrictions
（excluding shares lent through refinancing business） | | | | | | | | Name of shareholder | Number of tradable shares
held without selling
restrictions | Class and number of shares | | | | | | | | Class of shares | Number | | | | | Shenzhen Baiyeyuan Investment Co., Ltd. (深圳市百业源
投资有限公司) | 895,653,653 | Ordinary shares
denominated in Renminbi | 895,653,653 | | | | | Might Seasons Limited | 35,929,699 | Ordinary shares
denominated in Renminbi | 35,929,699 | | | | | Hong Kong Securities Clearing Company Limited | 34,206,023 | Ordinary shares
denominated in Renminbi | 34,206,023 | | | | | Zhang Yongliang | 16,242,296 | Ordinary shares
denominated in Renminbi | 16,242,296 | | | | | Agriculture Bank of China Limited-CSI 500 Exchange
Traded Index Securities Investment Fund | 15,938,148 | Ordinary shares
denominated in Renminbi | 15,938,148 | | | | | Tang Wusheng | 13,233,300 | Ordinary shares
denominated in Renminbi | 13,233,300 | | | | | Rui Life Insurance Co., Ltd. -Own fund | 12,739,218 | Ordinary shares
denominated in Renminbi | 12,739,218 | | | | | Bank of Shanghai Co., Ltd.－Yinhua CSI Innovative Drug
Industry Trading Open-end Index Securities Investment
Fund | 10,682,920 | Ordinary shares
denominated in Renminbi | 10,682,920 | | | | | Joincare Pharmaceutical Group Industry Co., Ltd. — the
Third Phase Ownership Scheme under Medium to Long-
term Business Partner Share Ownership Scheme | 9,370,400 | Ordinary shares
denominated in Renminbi | 9,370,400 | | | | | CPIC Fund -China Pacific Life Insurance Co., Ltd. -with-
profit insurance-CPIC Fund China Pacific Life Equity
Relative Income (Guaranteed Dividend) single asset
management plan | 7,957,200 | Ordinary shares
denominated in Renminbi | 7,957,200 | | | | | Description of connection or acting-in-concert relationship
of the above shareholders | There was no connection or acting-in-concert relationship between Shenzhen
Baiyeyuan Investment Co., Ltd., a controlling shareholder of the Company,
and other shareholders; whether there is connection or acting-in-concert
relationship among other shareholders is unknown. | | | | | | | Description of the participation of the top 10 shareholders
and the top 10 shareholders without selling restrictions in
margin financing and securities lending and refinancing
business (if any) | Shareholder Zhang Yongliang holds 15,200,296 shares of the Company
through a credit and guarantee account, and shareholder Tang Wusheng
holds 3,456,600 shares of the Company through a credit and guarantee
account. | | | | | |
Participation of shareholders holding over 5%, the top 10 shareholders, and the top 10 shareholders
without selling restriction in securities lending transactions of refinancing business □Applicable √N/A
Changes in the top 10 shareholders and the top 10 shareholders without selling restriction due to securities lending/returning transactions of refinancing business compared to the previous period □Applicable √N/A
III. OTHER REMINDERS
Other important information regarding the Company’s operations during the Reporting Period to which
investors should be reminded to pay attention.
√Applicable □N/A
Use of Proceeds
Pursuant to the Self-Regulatory Guidelines for Listed Companies on the Shanghai Stock Exchange No. 1 – Standardized Operation, upon the completion of all projects funded by the proceeds, any remaining proceeds (including interest income) shall be subject to review and approval by the board of
directors of the listed company, and the sponsor or independent financial adviser shall issue a clear opinion
thereon. The company shall make a timely announcement after the board’s deliberation. If the remaining
proceeds (including interest income) account for more than 10% of the net proceeds raised, such matter
shall also be submitted to the general meeting of shareholders for approval. If the remaining proceeds
(including interest income) are less than RMB 5 million or less than 5% of the net proceeds raised, the
above procedures may be exempted, and the use of such remaining proceeds shall be disclosed in the most
recent periodic report.
As of 30 September 2025, the proceeds raised from the Company’s rights issue have been fully utilized, and all projects funded by the rights issue have been completed. The Company will cancel the
designated proceeds account, and the Tripartite Supervision Agreement on the Management of Proceeds
entered into among the Company, the sponsor institution, and the commercial bank will accordingly be
terminated.
IV. QUARTERLY FINANCIAL STATEMENTS
(I) Audit Opinion
□Applicable √N/A
(II) Financial Statements
Consolidated Balance Sheet
30 September 2025
Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd. Unit: Yuan Currency: RMB Audit status: Unaudited
| Item | 30 September 2025 | 31 December 2024 | | Current assets: | | | | Monetary funds | 14,516,558,903.45 | 14,851,977,121.94 | | Financial assets held for trading | 1,205,846,281.06 | 89,363,055.07 | | Notes receivable | 1,493,544,063.87 | 1,951,213,189.48 | | Accounts receivable | 2,840,521,242.56 | 2,429,891,052.01 | | Receivables financing | | | | Prepayments | 256,679,088.79 | 241,379,213.79 | | Other receivables | 70,426,958.95 | 51,166,649.86 | | In which: Interests receivable | | | | Dividends receivable | | | | Inventories | 2,304,853,727.18 | 2,621,343,117.50 | | Contract assets | | | | Assets held-for-sale | 54,291,127.30 | 54,029,237.68 | | Non-current assets due within one year | 821,335,346.22 | 556,410,803.22 | | Other current assets | 232,152,185.08 | 159,087,536.76 | | Total current assets | 23,796,208,924.46 | 23,005,860,977.31 | | Non-current assets: | | | | Debt investment | | | | Other debt investment | | | | Long-term receivables | | | | Long-term equity investment | 1,488,646,760.50 | 1,446,298,598.46 | | Other equity instrument investments | 1,035,146,311.74 | 1,026,548,743.15 | | Other non-current financial assets | | | | Investment properties | 15,486,666.99 | 16,117,329.57 | | Fixed assets | 5,428,917,319.74 | 5,689,216,337.13 | | Construction in progress | 587,360,711.06 | 531,063,771.79 | | Productive biological assets | | | | Oil and gas assets | | | | Right-of-use assets | 38,188,436.24 | 38,626,733.57 | | Intangible assets | 712,479,094.30 | 687,430,720.95 | | Development expenditures | 516,552,277.31 | 362,703,730.11 | | Goodwill | 636,339,503.82 | 636,339,503.82 | | Long-term deferred expenses | 291,541,320.42 | 319,396,628.88 | | Deferred income tax assets | 803,011,996.73 | 685,468,536.85 | | Other non-current assets | 663,773,428.95 | 1,273,057,844.54 | | Total non-current assets | 12,217,443,827.80 | 12,712,268,478.82 | | Total assets | 36,013,652,752.26 | 35,718,129,456.13 | | Current liabilities: | | | | Short-term loans | 2,540,000,000.00 | 2,455,000,000.00 | | Financial liabilities held for trading | 7,203,215.23 | 9,046,554.29 | | Notes payable | 1,225,622,493.37 | 1,384,943,947.17 | | Accounts payable | 727,051,805.59 | 765,512,193.23 | | Receipts in advance | | | | Contract liabilities | 87,619,945.54 | 142,395,539.21 | | Employee benefits payable | 391,834,152.77 | 473,571,305.45 | | Taxes payable | 312,316,919.40 | 263,380,339.80 | | Other payables | 3,386,626,188.81 | 3,369,115,240.67 | | In which: Interests payable | | | | Dividends payable | 9,073,481.38 | 9,890,041.38 | | Liabilities held-for-sale | | | | Non-current liabilities due within one year | 357,065,332.74 | 395,975,991.36 | | Other current liabilities | 5,048,262.96 | 11,841,940.51 | | Total current liabilities | 9,040,388,316.41 | 9,270,783,051.69 | | Non-current liabilities: | | | | Long-term loans | 2,275,001,774.57 | 2,424,635,112.37 | | Bonds payable | | | | Lease liabilities | 21,760,722.99 | 19,975,819.77 | | Long-term payables | | | | Long-term payroll payable | | | | Estimated liabilities | | | | Deferred income | 322,585,129.11 | 334,970,008.52 | | Deferred income tax liabilities | 271,314,904.50 | 267,622,684.50 | | Other non-current liabilities | | | | Total non-current liabilities | 2,890,662,531.17 | 3,047,203,625.16 | | Total liabilities | 11,931,050,847.58 | 12,317,986,676.85 | | Owner's equity (or shareholder's equity): | | | | Paid-in capital | 1,829,453,386.00 | 1,874,200,420.00 | | Other equity instruments | | | | In which: Preferred shares | | | | Perpetual debts | | | | Capital reserve | 1,025,263,624.61 | 1,654,383,491.41 | | Less: Treasury shares | | 328,221,279.42 | | Other comprehensive income | -86,037,198.18 | -41,177,547.42 | | Special reserve | | | | Surplus reserve | 883,875,480.72 | 883,841,583.49 | | General Risk Provision | | | | Undistributed profits | 11,213,966,011.30 | 10,491,692,921.28 | | Total owner's equity (or shareholder's equity)
attributable to the parent | 14,866,521,304.45 | 14,534,719,589.34 | | Minority shareholder's equity | 9,216,080,600.23 | 8,865,423,189.94 | | Total owner's equity (or shareholder's equity) | 24,082,601,904.68 | 23,400,142,779.28 | | Total liabilities and owner's equity (or
shareholder's equity) | 36,013,652,752.26 | 35,718,129,456.13 |
Person-in-charge of the Person-in-charge of the Person-in-charge of the Company: Zhu Baoguo Company's accounting work: accounting department: Qiu Qingfeng Guo Chenlu
Consolidated Income Statement
From January to September, 2025
Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd. Unit: Yuan Currency: RMB Audit status: Unaudited
| Item | First three quarters
(January to September)
for 2025 | First three quarters
(January to September)
for 2024 | | I. Total revenues | 11,477,806,949.62 | 11,898,828,905.02 | | In which: Operating revenues | 11,477,806,949.62 | 11,898,828,905.02 | | II. Total operating costs | 8,763,958,191.70 | 9,121,682,123.61 | | In which: Operating costs | 4,254,948,410.68 | 4,393,919,087.41 | | Operating tax and surcharges | 142,756,194.02 | 137,567,242.03 | | Selling expenses | 3,033,074,349.23 | 2,951,059,287.90 | | Administrative expenses | 664,897,598.24 | 708,729,617.84 | | R&D expenses | 931,015,773.09 | 1,036,376,310.06 | | Financial expenses | -262,734,133.56 | -105,969,421.63 | | In which: Interest expenses | 66,818,990.15 | 94,972,898.62 | | Interest income | 364,347,873.71 | 245,985,558.70 | | Add: Other income | 120,140,425.68 | 124,184,202.58 | | Income from investments (loss is
indicated by“-”) | 64,826,880.04 | 51,650,239.89 | | In which: Income from investments
in associates and joint ventures | 59,369,920.92 | 34,370,020.06 | | Gains from derecognition of financial
assets at amortized cost | | | | Gains from net exposure hedges (loss
is indicated by“-”) | | | | Gains from changes in fair values
(loss is indicated by“-”) | 3,330,943.14 | -5,736,443.62 | | Losses of credit impairment (loss is
indicated by“-”) | -10,074,239.15 | -797,210.83 | | Assets impairment loss (loss is
indicated by“-”) | -20,885,370.43 | -113,694,072.70 | | Gains from disposal of assets (loss is
indicated by“-”) | -315,529.31 | -370,399.04 | | III. Operating profit (loss is indicated
by“-”) | 2,870,871,867.89 | 2,832,383,097.69 | | Add: Non-operating income | 6,359,949.10 | 6,920,279.40 | | Less: Non-operating expenses | 24,496,178.28 | 19,988,508.91 | | IV. Total profit (loss is indicated by“-”) | 2,852,735,638.71 | 2,819,314,868.18 | | Less: Income tax expenses | 408,174,143.65 | 385,618,343.11 | | V. Net profit (loss is indicated by“-”) | 2,444,561,495.06 | 2,433,696,525.07 | | (I) Classified by business continuity | | | | 1. Net profit from ongoing operation
(loss is indicated by“-”) | 2,444,561,495.06 | 2,433,696,525.07 | | 2. Net profit from discontinuing
operation (loss is indicated by“-”) | | | | (II) Classified by ownership | | | | 1.Net profit attributable to shareholders
of the parent (loss is indicated by“-”) | 1,091,214,131.28 | 1,111,560,063.92 | | 2.Profit and loss of minority
shareholders (loss is indicated by“-”) | 1,353,347,363.78 | 1,322,136,461.15 | | VI. Other comprehensive income, net of
tax | -78,933,476.63 | -86,688,069.37 | | (I) Other comprehensive income
attributable to owners of the parent, net
of tax | -48,215,089.89 | -59,369,859.17 | | 1. Other comprehensive income that
cannot be reclassified into profit or loss | -7,460,439.05 | -58,031,748.84 | | (1) Changes from remeasurement of
defined benefit plans | | | | (2) Other comprehensive income that
cannot be reclassified into profit or loss
under the equity method | | | | (3) Changes in fair value of
investments in other equity instruments | -7,460,439.05 | -58,031,748.84 | | (4) Changes in fair value of the
enterprise's own credit risks | | | | 2. Other comprehensive income that
will be reclassified into profit or loss | -40,754,650.84 | -1,338,110.33 | | (1) Other comprehensive income that
can be reclassified into profit or loss under
the equity method | 2,298.84 | -174,001.08 | | (2) Changes in fair value of other
debt investments | | | | (3) Amount of financial assets
reclassified into other comprehensive
income | | | | (4) Provision for credit impairment of
other debt investments | | | | (5) Reserve for cash flow hedges | | | | (6) Exchange translation differences
on financial statements denominated in
foreign currencies | -40,756,949.68 | -1,164,109.25 | | (7) Others | | | | (II) Other comprehensive income
attributable to minority shareholders, net
of tax | -30,718,386.74 | -27,318,210.20 | | VII. Total comprehensive income | 2,365,628,018.43 | 2,347,008,455.70 | | (I) Total comprehensive income
attributable to owners of the parent
company | 1,042,999,041.39 | 1,052,190,204.75 | | (II) Total comprehensive income
attributable to minority shareholders | 1,322,628,977.04 | 1,294,818,250.95 | | Ⅷ. Earnings per share | | | | (I) Basic earnings per share (RMB/share) | 0.60 | 0.59 | | (II) Diluted earnings per share
(RMB/share) | 0.60 | 0.59 |
Person-in-charge of the Person-in-charge of the Person-in-charge of the Company: Zhu Baoguo Company's accounting work: accounting department: Qiu Qingfeng Guo Chenlu
Consolidated Cash Flow Statement
From January to September 2025
Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd. Unit: Yuan Currency: RMB Audit status: Unaudited
| Item | First three quarters
(January to September)
for 2025 | First three quarters
(January to September)
for 2024 | | I. Cash flow from operating activities: | | | | Cash received from sales of goods and
rendering of services | 12,391,479,624.95 | 12,943,223,324.92 | | Tax refunds received | 122,369,837.96 | 101,353,328.18 | | Other cash received related to operating
activities | 482,797,216.58 | 422,265,935.11 | | Subtotal of cash inflow from operating
activities | 12,996,646,679.49 | 13,466,842,588.21 | | Cash paid for goods and services | 3,345,995,774.10 | 3,827,753,296.70 | | Cash paid to and on behalf of employees | 1,974,044,172.40 | 1,933,905,112.85 | | Payments of all types of taxes | 1,310,417,850.36 | 1,480,113,236.04 | | Other cash paid related to operating activities | 3,364,786,910.56 | 3,611,465,441.56 | | Subtotal of cash outflow in operating
activities | 9,995,244,707.42 | 10,853,237,087.15 | | Net cash flow from operating activities | 3,001,401,972.07 | 2,613,605,501.06 | | II. Cash flow from investing activities: | | | | Cash received from disposal of investment | 6,535,244,466.28 | 684,870,511.47 | | Cash received from investment income | 29,959,571.02 | 21,390,153.27 | | Net cash received from disposal of fixed
assets, intangible assets and other long-term
assets | 30,682,189.50 | 474,130.00 | | Net cash received from disposal of subsidiaries
and other business units | | 8,392,000.00 | | Other cash received related to investing
activities | 125,249.03 | | | Subtotal of cash inflow from investing
activities | 6,596,011,475.83 | 715,126,794.74 | | Cash paid for purchase and construction of
fixed assets, intangible assets and other long-
term assets | 644,122,147.11 | 737,034,937.83 | | Cash paid for investment | 7,300,656,109.43 | 1,160,648,306.49 | | Net cash paid for acquisition of subsidiaries
and other business units | | | | Other cash paid related to investing activities | 4,652,230.29 | 1,404,603.34 | | Subtotal of cash outflow in investing
activities | 7,949,430,486.83 | 1,899,087,847.66 | | Net cash flow from investing activities | -1,353,419,011.00 | -1,183,961,052.92 | | III. Cash flow from financing activities: | | | | Cash received from capital contribution | 32,149,064.38 | 261,660,059.73 | | In which: Cash received from investment by
minority interests of subsidiaries | 32,149,064.38 | 165,101,999.95 | | Cash received from borrowings | 3,121,774,844.45 | 3,730,993,152.42 | | Other cash received related to financing
activities | | 1,062,615.02 | | Subtotal of cash inflow from financing
activities | 3,153,923,908.83 | 3,993,715,827.17 | | Cash repayments of amounts borrowed | 3,227,463,209.00 | 4,293,197,628.28 | | Cash payments for interest expenses and
distribution of dividends or profits | 1,049,814,070.80 | 1,447,407,636.60 | | In which: Dividends and profit paid minority
interests of subsidiaries | 626,711,689.41 | 1,007,311,935.18 | | Other cash payments related to financing
activities | 762,551,675.46 | 400,728,019.90 | | Subtotal of cash outflow in financing
activities | 5,039,828,955.26 | 6,141,333,284.78 | | Net cash flow from financing activities | -1,885,905,046.43 | -2,147,617,457.61 | | IV. Effect of exchange rate fluctuations on
cash and cash equivalents | -97,585,733.14 | -37,426,542.59 | | V. Net increase in cash and cash equivalents | -335,507,818.50 | -755,399,552.06 | | Add: Opening balance of cash and cash
equivalents | 14,842,645,678.32 | 15,340,869,372.73 | | VI. Closing balance of cash and cash
equivalents | 14,507,137,859.82 | 14,585,469,820.67 |
（未完）
|
|
